{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:49:04Z","timestamp":1785714544442,"version":"3.56.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Currently, computed tomography (CT) is used for lung cancer screening (LCS) among populations with various levels of compliance to the eligibility criteria from the US Preventive Services Task Force (USPSTF) recommendations and may represent suboptimal allocation of health care resources.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the appropriateness of CT LCS according to the USPSTF eligibility criteria.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study used the 2019 Behavioral Risk Factor Surveillance System (BRFSS) survey. Participants included individuals who responded to the LCS module administered in 20 states and had valid answers to questions regarding screening and smoking history. Data were analyzed between October 2021 and August 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Screening eligibility groups were categorized according to the USPSTF 2013 recommendations, and subgroups of individuals who underwent LCS were analyzed.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Main outcomes included LCS among the screening-eligible population and the proportions of the screened populations according to compliance categories established from the USPSTF 2013 and 2021 recommendations. In addition, the association between respondents\u2019 characteristics and LCS was evaluated for the subgroup who were screened despite not meeting any of the 3 USPSTF screening criteria: age, pack-year, and years since quitting smoking.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 96\u202f097 respondents were identified for the full study cohort, and 2 subgroups were constructed: (1) 3374 respondents who reported having a CT or computerized axial tomography to check for lung cancer and (2) 33\u202f809 respondents who did not meet any screening eligibility criteria. The proportion of participants who were under 50 years old was 53.1%; between 50 and 54, 9.1%; between 55 and 79, 33.8%; and over 80, 4.0%. A total of 51\u202f536 (50.9%) of the participants were female. According to the USPSTF 2013 recommendation, 807 (12.8%) of the screening-eligible population underwent LCS. Among those who were screened, only 807 (20.9%) met all 3 screening eligibility criteria, whereas 538 (20.1%) failed to meet any criteria. Among respondents in subgroup 2, being of older age and having a history of stroke, chronic obstructive pulmonary disease, kidney disease, or diabetes were associated with higher likelihood of LCS.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study of the BRFSS 2019 survey, the low uptake rate among screening-eligible patients undermined the goal of LCS of early detection. Suboptimal screening patterns could increase health system costs and add financial stress, psychological burden, and physical harms to low-risk patients, while failing to provide high-quality preventive services to individuals at high risk of lung cancer.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.43163","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:33:24Z","timestamp":1669048404000},"page":"e2243163","source":"Crossref","is-referenced-by-count":39,"title":["Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force"],"prefix":"10.1001","volume":"5","author":[{"given":"Yu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen Elaine","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Tak","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Administration, University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Vlahos","sequence":"additional","affiliation":[{"name":"Thoracic Imaging Department, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Volk","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"1","key":"zoi221216r2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi221216r3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial.","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi221216r4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/ijc.v146.6","article-title":"Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial.","volume":"146","author":"Becker","year":"2020","journal-title":"Int J Cancer"},{"issue":"5","key":"zoi221216r5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening.","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi221216r6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7326\/M13-2771","article-title":"Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi221216r9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.v127.5","article-title":"Lung cancer screening eligibility and use with low-dose computed tomography: results from the 2018 Behavioral Risk Factor Surveillance System cross-sectional survey.","volume":"127","author":"Narayan","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"zoi221216r10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamainternmed.2016.9016","article-title":"Use of CT and chest radiography for lung cancer screening before and after publication of screening guidelines: intended and unintended uptake.","volume":"177","author":"Huo","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"1","key":"zoi221216r11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.amepre.2018.07.030","article-title":"Lung cancer screening inconsistent with U.S. Preventive Services Task Force recommendations.","volume":"56","author":"Richards","year":"2019","journal-title":"Am J Prev Med"},{"issue":"9","key":"zoi221216r12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/jnci\/djk153","article-title":"A risk model for prediction of lung cancer.","volume":"99","author":"Spitz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"zoi221216r13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.lungcan.2020.07.007","article-title":"Risk-based lung cancer screening: a systematic review.","volume":"147","author":"Toumazis","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"zoi221216r14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.amepre.2019.03.015","article-title":"Lung cancer screening utilization: a Behavioral Risk Factor Surveillance System analysis.","volume":"57","author":"Zahnd","year":"2019","journal-title":"Am J Prev Med"},{"issue":"9","key":"zoi221216r15","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s11606-020-06236-9","article-title":"Lung cancer screening uptake: analysis of BRFSS 2018.","volume":"36","author":"Kee","year":"2021","journal-title":"J Gen Intern Med"},{"key":"zoi221216r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2021.100284","article-title":"Factors associated with low-dose CT lung cancer screening participation in a high burden state: results from the 2017-2018 BRFSS.","volume":"28","author":"Sedani","year":"2021","journal-title":"J Cancer Policy"},{"issue":"8","key":"zoi221216r17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.15585\/mmwr.mm6908a1","article-title":"Screening for lung cancer\u201410 states, 2017.","volume":"69","author":"Richards","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi221216r18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.chest.2019.08.2176","article-title":"Lung cancer screening uptake in the United States.","volume":"157","author":"Yong","year":"2020","journal-title":"Chest"},{"key":"zoi221216r19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.canep.2019.03.009","article-title":"LDCT lung cancer screening eligibility and use of CT scans for lung cancer among sexual minorities.","volume":"60","author":"Veliz","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"zoi221216r28","first-page":"4636","article-title":"Cardiovascular disease and the risk of lung cancer, the HUNT study.","volume":"42","author":"Amundsen","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"zoi221216r29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.lungcan.2015.08.017","article-title":"The relationship between COPD and lung cancer.","volume":"90","author":"Durham","year":"2015","journal-title":"Lung Cancer"},{"key":"zoi221216r30","doi-asserted-by":"publisher","first-page":"S1267","DOI":"10.21037\/jtd","article-title":"Lung metastasectomy following kidney tumors: outcomes and prognostic factors from a single-center experience.","volume":"9","author":"Meacci","year":"2017","journal-title":"J Thorac Dis"},{"issue":"10","key":"zoi221216r31","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.ejca.2013.02.025","article-title":"Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies.","volume":"49","author":"Lee","year":"2013","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi221216r32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/lmt.14.41","article-title":"Assessing the benefits and harms of low-dose computed tomography screening for lung cancer.","volume":"3","author":"Pinsky","year":"2014","journal-title":"Lung Cancer Manag"},{"issue":"7","key":"zoi221216r33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.7326\/M14-2086","article-title":"Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.","volume":"162","author":"Pinsky","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"zoi221216r34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.29874","article-title":"Updated analysis of complication rates associated with invasive diagnostic procedures after lung cancer screening.","volume":"3","author":"Zhao","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi221216r35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamainternmed.2018.6277","article-title":"Complication rates and downstream medical costs associated with invasive diagnostic procedures for lung abnormalities in the community setting.","volume":"179","author":"Huo","year":"2019","journal-title":"JAMA Intern Med"},{"key":"zoi221216r36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jacr.2019.01.001","article-title":"Challenges and opportunities for lung cancer screening in rural America.","volume":"16","author":"Odahowski","year":"2019","journal-title":"J Am Coll Radiol"},{"key":"zoi221216r37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacr.2021.09.015","article-title":"Total and out-of-pocket costs of procedures after lung cancer screening in a national commercially insured population: estimating an episode of care.","volume":"11","author":"Tailor","year":"2022","journal-title":"J Am Coll Radiol"},{"issue":"3","key":"zoi221216r39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000261","article-title":"The ACA and cancer screening and diagnosis.","volume":"23","author":"Sabik","year":"2017","journal-title":"Cancer J"},{"issue":"3","key":"zoi221216r40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1377\/hlthaff.2018.05015","article-title":"Spillover effects from a consumer-based intervention to increase high-value preventive care.","volume":"38","author":"Cliff","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"15","key":"zoi221216r41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e18909","article-title":"Downstream revenue attributable to lung cancer screening program serving a minority predominant population.","volume":"36","author":"Plumb","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi221216r42","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/j.chest.2021.06.063","article-title":"Screening for lung cancer: CHEST guideline and expert panel report.","volume":"160","author":"Mazzone","year":"2021","journal-title":"Chest"},{"key":"zoi221216r43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2288-13-49","article-title":"A systematic review of publications assessing reliability and validity of the Behavioral Risk Factor Surveillance System (BRFSS), 2004-2011.","volume":"13","author":"Pierannunzi","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"zoi221216r44","first-page":"S3","article-title":"Reliability and validity of measures from the Behavioral Risk Factor Surveillance System (BRFSS).","volume":"46","author":"Nelson","year":"2001","journal-title":"Soz Praventivmed"},{"issue":"1","key":"zoi221216r45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.18043\/ncm.80.1.19","article-title":"Opinions and practices of lung cancer screening by physician specialty.","volume":"80","author":"Henderson","year":"2019","journal-title":"N C Med J"},{"issue":"6","key":"zoi221216r46","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/j.cllc.2017.05.003","article-title":"Attitudes about lung cancer screening: primary care providers versus specialists.","volume":"18","author":"Rajupet","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"zoi221216r1","unstructured":"American Cancer Society. Key statistics for lung cancer. 2021. Accessed October 27, 2021. https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/key-statistics.html"},{"key":"zoi221216r7","unstructured":"Jonas? DE, Reuland? DS, Reddy? SM, . Screening for lung cancer with low-dose computed tomography: an evidence review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality. 2021. Accessed October 14, 2022. https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK568573\/"},{"key":"zoi221216r8","unstructured":"US Preventive Services Task Force. Final recommendation statement: lung cancer: screening. Published 2021. Updated 2021 March 9. Accessed October 19, 2021. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening"},{"key":"zoi221216r20","unstructured":"US Centers for Disease Control and Prevention. About BRFSS. Updated May 16 2014. Accessed October 19, 2021. https:\/\/www.cdc.gov\/brfss\/about\/index.htm"},{"key":"zoi221216r21","unstructured":"US Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System overview: BRFSS 2019. Accessed Nov 30, 2021. https:\/\/www.cdc.gov\/brfss\/annual_data\/2019\/pdf\/overview-2019-508.pdf"},{"key":"zoi221216r22","unstructured":"Equator Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. equator-network.org. 2022. Accessed August 15, 2022. https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/"},{"key":"zoi221216r23","unstructured":"US Centers for Disease Control and Prevention. CDC\u2014BRFSS\u2014questionnaires 2019 modules by state by data set and weight. Published 2020. Updated August 28, 2020. Accessed October 19, 2021. https:\/\/www.cdc.gov\/brfss\/questionnaires\/modules\/state2019.htm"},{"key":"zoi221216r24","unstructured":"US Centers for Disease Control and Prevention. LLCP 2019 codebook report overall version data weighted with _LLCPWT Behavioral Risk Factor Surveillance System. Published 2020. Updated July 31, 2020. Accessed October 20, 2021. https:\/\/www.cdc.gov\/brfss\/annual_data\/2019\/pdf\/codebook19_llcp-v2-508.HTML"},{"key":"zoi221216r25","unstructured":"National Cancer Institute. Pack year. 2021. Accessed October 21, 2021. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/pack-year"},{"key":"zoi221216r26","unstructured":"US Centers for Disease Control and Prevention. Using the BRFSS COPD data. 2021. Accessed October 20, 2021. https:\/\/www.cdc.gov\/copd\/pdfs\/brfss_copd_syntax.pdf"},{"key":"zoi221216r27","unstructured":"Centers for Medicare & Medicaid Services. Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). 2015. Accessed December 28, 2021. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx?proposed=N&NCAId=274"},{"key":"zoi221216r38","unstructured":"American Lung Association. Lung cancer screening: coverage in health insurance plans. 2021. Accessed December 15, 2021. https:\/\/www.lung.org\/getmedia\/3229a1fe-b419-40e3-bb93-58acf60496e5\/lung-cancer-screening-coverage.pdf"},{"key":"zoi221216r47","unstructured":"US Centers for Disease Control and Prevention. QuickStats: age-adjusted lung cancer death rates, by state\u2014national vital statistics system, United States, 2018. 2020. Accessed August 15, 2022. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6936a8.htm#:~:text=The%20five%20states%20with%20the,%2C%20and%20Oklahoma%20"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798824\/liu_2022_oi_221216_1668176846.50255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:33:34Z","timestamp":1669048414000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43163","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]}}}